Earnings Releases·Nov 2, 2026, 4:07 PM ET

CRISPR Therapeutics — Third Quarter 2026 Earnings Summary

CASGEVY revenue surged to $99 million in Q3 2026, representing 30% quarter-over-quarter growth and nearly six times the prior year's figure, driving total revenue to $12.7 million from $0.9 million year-over-year.
Net loss widened to $111.4 million from $106.4 million in Q3 2025, while R&D expenses rose to $71.9 million due to increased external costs and $11.7 million in acquired in-process R&D expenses.
Cash and marketable securities increased to $2,276.6 million as of September 30, 2026, following $585.4 million in net proceeds from convertible senior notes issued in March 2026.
Management outlined a "pivotal period" with upcoming data presentations for CTX310 and zugo-cel in November 2026, alongside expected updates on CTX611 and zugo-cel trials in the second half of 2026.
Key leadership changes include the appointment of A.J. Silver as Chief Financial Officer and Siva Sakhamuri as Chief Technical Officer, while CASGEVY approvals expanded to include children aged 2 and older in the U.S. and additional international markets.